Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib

OBJECTIVE: Anti‐MDA5 antibody‐positive dermatomyositis (DM) is a rare clinical autoimmune disease, and anti‐MDA5‐positive DM with interstitial lung disease (ILD) is the most important cause of death in DM patients. We reported the efficacy of the JAK1/3 inhibitor tofacitinib as an anti‐MDA5‐negative...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zong, Yao, Xiaoling, Tang, Fang, Ma, Wukai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266132/
https://www.ncbi.nlm.nih.gov/pubmed/37382261
http://dx.doi.org/10.1002/iid3.897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266132/
https://www.ncbi.nlm.nih.gov/pubmed/37382261
http://dx.doi.org/10.1002/iid3.897

Ejemplares similares